Literature DB >> 33619116

NPM-ALK-Induced Reprogramming of Mature TCR-Stimulated T Cells Results in Dedifferentiation and Malignant Transformation.

David L Cookmeyer1,2, Damian Maseda1,2, John K Everett1, Jan M Pawlicki1,2, Fang Wei1,2, Hong Kong1,2, Qian Zhang3, Hong Y Wang3, John W Tobias4, David M Walter1,2, Kelly M Zullo1,2, Sarah Javaid5, Amanda Watkins5, Mariusz A Wasik3, Frederic D Bushman1, James L Riley6,2.   

Abstract

Fusion genes including NPM-ALK can promote T-cell transformation, but the signals required to drive a healthy T cell to become malignant remain undefined. In this study, we introduce NPM-ALK into primary human T cells and demonstrate induction of the epithelial-to-mesenchymal transition (EMT) program, attenuation of most T-cell effector programs, reemergence of an immature epigenomic profile, and dynamic regulation of c-Myc, E2F, and PI3K/mTOR signaling pathways early during transformation. A mutant of NPM-ALK failed to bind several signaling complexes including GRB2/SOS, SHC1, SHC4, and UBASH3B and was unable to transform T cells. Finally, T-cell receptor (TCR)-generated signals were required to achieve T-cell transformation, explaining how healthy individuals can harbor T cells with NPM-ALK translocations. These findings describe the fundamental mechanisms of NPM-ALK-mediated oncogenesis and may serve as a model to better understand factors that regulate tumor formation. SIGNIFICANCE: This investigation into malignant transformation of T cells uncovers a requirement for TCR triggering, elucidates integral signaling complexes nucleated by NPM-ALK, and delineates dynamic transcriptional changes as a T cell transforms.See related commentary by Spasevska and Myklebust, p. 3160. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33619116      PMCID: PMC8260452          DOI: 10.1158/0008-5472.CAN-20-2297

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   13.312


  62 in total

1.  Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells.

Authors:  Joseph A Fraietta; Christopher L Nobles; Morgan A Sammons; Stefan Lundh; Shannon A Carty; Tyler J Reich; Alexandria P Cogdill; Jennifer J D Morrissette; Jamie E DeNizio; Shantan Reddy; Young Hwang; Mercy Gohil; Irina Kulikovskaya; Farzana Nazimuddin; Minnal Gupta; Fang Chen; John K Everett; Katherine A Alexander; Enrique Lin-Shiao; Marvin H Gee; Xiaojun Liu; Regina M Young; David Ambrose; Yan Wang; Jun Xu; Martha S Jordan; Katherine T Marcucci; Bruce L Levine; K Christopher Garcia; Yangbing Zhao; Michael Kalos; David L Porter; Rahul M Kohli; Simon F Lacey; Shelley L Berger; Frederic D Bushman; Carl H June; J Joseph Melenhorst
Journal:  Nature       Date:  2018-05-30       Impact factor: 49.962

2.  Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1.

Authors:  K Pulford; L Lamant; S W Morris; L H Butler; K M Wood; D Stroud; G Delsol; D Y Mason
Journal:  Blood       Date:  1997-02-15       Impact factor: 22.113

3.  ARID1A mutations in endometriosis-associated ovarian carcinomas.

Authors:  Kimberly C Wiegand; Sohrab P Shah; Osama M Al-Agha; Yongjun Zhao; Kane Tse; Thomas Zeng; Janine Senz; Melissa K McConechy; Michael S Anglesio; Steve E Kalloger; Winnie Yang; Alireza Heravi-Moussavi; Ryan Giuliany; Christine Chow; John Fee; Abdalnasser Zayed; Leah Prentice; Nataliya Melnyk; Gulisa Turashvili; Allen D Delaney; Jason Madore; Stephen Yip; Andrew W McPherson; Gavin Ha; Lynda Bell; Sian Fereday; Angela Tam; Laura Galletta; Patricia N Tonin; Diane Provencher; Dianne Miller; Steven J M Jones; Richard A Moore; Gregg B Morin; Arusha Oloumi; Niki Boyd; Samuel A Aparicio; Ie-Ming Shih; Anne-Marie Mes-Masson; David D Bowtell; Martin Hirst; Blake Gilks; Marco A Marra; David G Huntsman
Journal:  N Engl J Med       Date:  2010-09-08       Impact factor: 91.245

4.  Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity.

Authors:  R Y Bai; P Dieter; C Peschel; S W Morris; J Duyster
Journal:  Mol Cell Biol       Date:  1998-12       Impact factor: 4.272

5.  Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies.

Authors:  Milos Aleksic; Nathaniel Liddy; Peter E Molloy; Nick Pumphrey; Annelise Vuidepot; Kyong-Mi Chang; Bent K Jakobsen
Journal:  Eur J Immunol       Date:  2012-10-16       Impact factor: 5.532

6.  Anaplastic large cell lymphoma arises in thymocytes and requires transient TCR expression for thymic egress.

Authors:  Tim I M Malcolm; Patrick Villarese; Camilla J Fairbairn; Laurence Lamant; Amélie Trinquand; C Elizabeth Hook; G A Amos Burke; Laurence Brugières; Katherine Hughes; Dominique Payet; Olaf Merkel; Ana-Iris Schiefer; Ibraheem Ashankyty; Shahid Mian; Mariusz Wasik; Martin Turner; Lukas Kenner; Vahid Asnafi; Elizabeth Macintyre; Suzanne D Turner
Journal:  Nat Commun       Date:  2016-01-12       Impact factor: 14.919

Review 7.  Overview of the Use of Murine Models in Leukemia and Lymphoma Research.

Authors:  Rebecca Kohnken; Pierluigi Porcu; Anjali Mishra
Journal:  Front Oncol       Date:  2017-02-20       Impact factor: 6.244

8.  ARID1A-mutated ovarian cancers depend on HDAC6 activity.

Authors:  Benjamin G Bitler; Shuai Wu; Pyoung Hwa Park; Yang Hai; Katherine M Aird; Yemin Wang; Yali Zhai; Andrew V Kossenkov; Ana Vara-Ailor; Frank J Rauscher; Weiping Zou; David W Speicher; David G Huntsman; Jose R Conejo-Garcia; Kathleen R Cho; David W Christianson; Rugang Zhang
Journal:  Nat Cell Biol       Date:  2017-07-24       Impact factor: 28.824

9.  Insights into the Pathogenesis of Anaplastic Large-Cell Lymphoma through Genome-wide DNA Methylation Profiling.

Authors:  Melanie R Hassler; Walter Pulverer; Ranjani Lakshminarasimhan; Elisa Redl; Julia Hacker; Gavin D Garland; Olaf Merkel; Ana-Iris Schiefer; Ingrid Simonitsch-Klupp; Lukas Kenner; Daniel J Weisenberger; Andreas Weinhaeusel; Suzanne D Turner; Gerda Egger
Journal:  Cell Rep       Date:  2016-10-04       Impact factor: 9.423

10.  Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency.

Authors:  Monica Ceccon; Maria Elena Boggio Merlo; Luca Mologni; Teresa Poggio; Lydia M Varesio; Matteo Menotti; Silvia Bombelli; Roberta Rigolio; Andrea D Manazza; Filomena Di Giacomo; Chiara Ambrogio; Giovanni Giudici; Cesare Casati; Cristina Mastini; Mara Compagno; Suzanne D Turner; Carlo Gambacorti-Passerini; Roberto Chiarle; Claudia Voena
Journal:  Oncogene       Date:  2015-12-14       Impact factor: 9.867

View more
  2 in total

1.  PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial.

Authors:  In-Young Jung; Simon F Lacey; Andrew J Rech; Megan M Davis; Carl H June; Joseph A Fraietta; Naomi B Haas; Vivek Narayan; Julie S Barber-Rotenberg; Wei-Ting Hwang; Priti Lal; Erica L Carpenter; Shannon L Maude; Gabriela Plesa; Neha Vapiwala; Anne Chew; Michael Moniak; Ronnie A Sebro; Michael D Farwell; Amy Marshall; Joan Gilmore; Lester Lledo; Karen Dengel; Sarah E Church; Tyler D Hether; Jun Xu; Mercy Gohil; Thomas H Buckingham; Stephanie S Yee; Vanessa E Gonzalez; Irina Kulikovskaya; Fang Chen; Lifeng Tian; Kyle Tien; Whitney Gladney; Christopher L Nobles; Hayley E Raymond; Elizabeth O Hexner; Donald L Siegel; Frederic D Bushman
Journal:  Nat Med       Date:  2022-03-21       Impact factor: 87.241

2.  De novo generation of the NPM-ALK fusion recapitulates the pleiotropic phenotypes of ALK+ ALCL pathogenesis and reveals the ROR2 receptor as target for tumor cells.

Authors:  Loélia Babin; Alice Darchen; Elie Robert; Zakia Aid; Rosalie Borry; Claire Soudais; Marion Piganeau; Anne De Cian; Carine Giovannangeli; Olivia Bawa; Charlotte Rigaud; Jean-Yves Scoazec; Lucile Couronné; Layla Veleanu; Agata Cieslak; Vahid Asnafi; David Sibon; Laurence Lamant; Fabienne Meggetto; Thomas Mercher; Erika Brunet
Journal:  Mol Cancer       Date:  2022-03-04       Impact factor: 27.401

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.